



Streptavidin

Cat. No.	Format	Size	Cat. No.	Format	Size
7105-01	Purified (UNLB)	5.0 mg	7105-10	R-phycoerythrin-Texas Red® (PE/TXRD)	0.1 mg
7105-01S	Purified (UNLB)	0.5 mg	7105-11L	Allophycocyanin (APC)	1.0 mg
7105-02	Fluorescein (FITC)	1.0 mg	7105-11M	Allophycocyanin (APC)	0.5 mg
7105-02S	Fluorescein (FITC)	0.5 mg	7105-11S	Allophycocyanin (APC)	0.1 mg
7105-03	Rhodamine (TRITC)	1.0 mg	7105-12	Cyanine 3 (CY3)	0.1 mg
7105-04	Alkaline Phosphatase (AP)	1.0 mL	7105-13L	Spectral Red® (SPRD)	0.5 mg
7105-05	Horseradish Peroxidase (HRP)	1.0 mL	7105-13S	Spectral Red® (SPRD)	0.1 mg
7105-06	β-galactosidase (BGAL)	1.0 mL	7105-15	Cyanine 5 (CY5)	1.0 mg
7105-07	Texas Red® (TXRD)	1.0 mg	7105-17L	R-phycoerythrin-Cyanine 7 (PE/CY7)	0.5 mg
7105-09L	R-phycoerythrin (PE)	1.0 mg	7105-17S	R-phycoerythrin-Cyanine 7 (PE/CY7)	0.1 mg
7105-09M	R-phycoerythrin (PE)	0.5 mg	7105-19L	Allophycocyanin-Cyanine 7 (APC/CY7)	0.5 mg
7105-09S	R-phycoerythrin (PE)	0.1 mg	7105-19S	Allophycocyanin-Cyanine 7 (APC/CY7)	0.1 mg

Description

Specificity	Biotin
Source	<i>E. coli</i>

Applications

Quality tested applications include –

ELISA ¹⁻¹¹
 FLISA
 FC ^{12,13}

Other referenced applications include –

ELISPOT ¹⁴⁻¹⁷
 IHC-FS ²¹
 IHC-PS ¹⁸
 ICC ²¹
 WB ^{8,11}
 Multiplex ^{19,20}

Working Dilutions

Flow Cytometry	FITC and CY3 conjugates	≤ 1 µg/10 ⁶ cells
	PE, PE/TXRD, and CY5 conjugates	≤ 0.2 µg/10 ⁶ cells
	APC, SPRD, and APC/CY7 conjugates	≤ 0.1 µg/10 ⁶ cells
	PE/CY7 conjugate	≤ 0.01 µg/10 ⁶ cells

For flow cytometry, the suggested use of these reagents is in a final volume of 100 µL

FLISA	FITC, TRITC, TXRD, and CY3 conjugates	1:100 – 1:400
	PE, APC, and CY5 conjugates	≤ 1 µg/mL
ELISA	AP conjugate	1:2,000 – 1:4,000
	HRP conjugate	1:4,000 – 1:8,000
	BGAL conjugate	1:500

Other Applications Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.

For Research Use Only. Not for Diagnostic or Therapeutic Use.

Handling and Storage

- The purified (UNLB) streptavidin is supplied as 5.0 mg protein in 1.0 mL or 0.5 mg in 1.0 mL of borate buffered saline, pH 8.2. *No preservatives or amine-containing buffer salts added.* Store at 2-8°C.
- The fluorescein (FITC) conjugate is supplied as 0.5 mg in 0.5 mL or 1.0 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The rhodamine (TRITC), Texas Red® (TXRD), and Cyanine 5 (CY5) conjugates are supplied as 1.0 mg in 1.0 mL of PBS/NaN₃. Store at 2-8°C.
- The alkaline phosphatase (AP) conjugate is supplied as 1.0 mL in a stock solution of 50 mM Tris/1 mM MgCl₂/50% glycerol, pH 8.0, containing NaN₃ as preservative. Store at 2-8°C or long-term at -20°C.
- The horseradish peroxidase (HRP) conjugate is supplied as 1.0 mL in a stock solution of 50% glycerol/50% PBS, pH 7.4. *No preservative added.* Store at 2-8°C or long-term at -20°C.
- The β-galactosidase (BGAL) conjugate is supplied as 1.0 mL in a stock solution of 50% glycerol/50% PBS containing NaN₃ as preservative. Store at 2-8°C or long-term at -20°C.
- The R-phycoerythrin (PE) and allophycocyanin (APC) conjugates are supplied 1.0 mg in 2.0 mL, 0.5 mg in 1.0 mL, or 0.1 mg in 0.2 mL of PBS/NaN₃ and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- The Cyanine 3 (CY3) conjugate is supplied as 0.1 mg in 0.2 mL of PBS/NaN₃. Store at 2-8°C.
- The R-phycoerythrin/Texas Red® (PE/TXRD) conjugate is supplied as 0.1 mg in 0.2 mL of PBS/NaN₃ and a stabilizing agent. **Do not freeze!**
- The Spectral Red® (SPRD), R-phycoerythrin-Cyanine 7 (PE/CY7), and allophycocyanin-Cyanine 7 (APC/CY7) conjugates are supplied as 0.5 mg in 1.0 mL or 0.1 mg in 0.2 mL of PBS/NaN₃ and a stabilizing agent. Store at 2-8°C. **Do not freeze!**
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

Warning

Some reagents contain sodium azide. Please refer to product specific SDS.

References

1. Pohlmeier L, Sonar SS, Rodewald H, Kopf M, Tortola L. Comparative analysis of the role of mast cells in murine asthma models using Kit-sufficient mast cell-deficient animals. *Allergy*. 2021;76:2030-43. (ELISA)
2. Honjo K, Russell RM, Li R, Liu W, Stoltz R, Tabengwa EM, et al. Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. *Cell Rep Med*. 2020;2:100164. (ELISA)
3. Hayuningtyas RA, Han M, Choi S, Kwak MS, Park IH, Lee J, et al. The collagen structure of C1q induces wound healing by engaging discoidin domain receptor 2. *Mol Med*. 2021;27:125. (ELISA)
4. Afkhami S, D'Agostino MR, Zhang A, Stacey HD, Marzok A, Kang A, et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. *Cell*. 2022;185:896-915. (ELISA)
5. Myzithras M, Lin S, Radden L, Hess Kenny C, Cai Z, MacDonald A, et al. Development of novel ultra-sensitive IL-11 target engagement assays to support mechanistic PK/PD modeling for an anti-IL-11 antibody therapeutic. *Mabs*. 2022;14:2104153. (ELISA)
6. Ekanger CT, Zhou F, Bohan D, Lotsberg ML, Ramnefjell M, Hoareau L, et al. Human organotypic airway and lung organoid cells of bronchiolar and alveolar differentiation are permissive to infection by influenza and SARS-CoV-2 respiratory virus. *Front Cell Infect Microbiol*. 2022;12:841447. (ELISA)
7. Ratswohl C, Vázquez García C, Ahmad AUW, Gonschior H, Lebedin M, Silvis CE, et al. A design strategy to generate a SARS-CoV-2 RBD vaccine that abrogates ACE2 binding and improves neutralizing antibody responses. *Eur J Immunol*. 2023;53:e2350408. (ELISA)
8. Tjærnhage E, Brown D, Bogen B, Andersen TK, Grødeland G. Trimeric, APC-targeted subunit vaccines protect mice against seasonal and pandemic influenza. *J Virol*. 2023;97:e0169422. (ELISA, WB)
9. Dangi T, Sanchez S, Lew MH, Awakoaiye B, Visvabharathy L, Richner JM. Pre-existing immunity modulates responses to mRNA boosters. *Cell Rep*. 2023;42:112167. (ELISA)
10. Remy C, Pintado E, Dunlop M, Schön S, Kleinpeter P, Rozanes H, et al. Design and selection of anti-PD-L1 single-domain antibody and tumor necrosis factor superfamily ligands for an optimal vectorization in an oncolytic virus. *Front Bioeng Biotechnol*. 2023;11:1247802. (ELISA)
11. Wei Y, Chen Q, Chen J, Zhou C, Geng S, Shi D, et al. Loss of α-1,2-mannosidase MAN1C1 promotes tumorigenesis of intrahepatic cholangiocarcinoma through enhancing CD133-FIP200 interaction. *Cell Rep*. 2023;42:113588. (ELISA, WB)
12. Liu H, Zhao Q, Tan L, Wu X, Huang R, Zuo Y, et al. Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma. *Cancer Cell*. 2023;41:693-710.e8. (FC)
13. Smith ES, Balch LA, Scrivens M, Shi S, Wang W, Harvey CD, et al. Use of poxvirus display to select antibodies specific for complex membrane antigens. *Mabs*. 2023;15:2249947. (FC)
14. Dagotto G, Ventura JD, Martinez DR, Anioke T, Chung BS, Siamatu M, et al. Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex. *NPJ Vaccines*. 2022;7:125. (ELISpot)
15. Garcia-Dominguez D, Henry C, Ma L, Jani H, Amato NJ, Manning T, et al. Altering the mRNA-1273 dosing interval impacts the kinetics, quality, and magnitude of immune responses in mice. *Front Immunol*. 2022;13:948335. (ELISpot)
16. Fan J, Li S, Zhang Y, Zheng J, Wang D, Liao Y, et al. Early emerging SARS-CoV-2 spike mutants are diversified in virologic properties but elicit compromised antibody responses. *Viruses*. 2023;15:2401. (ELISpot)
17. Huang H, Li Y, Zhang G, Ruan G, Zhu Z, Chen W, et al. The RNA-binding protein hnRNP F is required for the germinal center B cell response. *Nat Commun*. 2023;14:1731. (ELISpot)
18. Horii Y, Iniwa T, Onitsuka M, Tsukimoto J, Tanaka Y, Ike H, et al. Reversal of neuroinflammation in novel GS model mice by single i.c.v. administration of CHO-derived rhCTSA precursor protein. *Mol Ther Methods Clin Dev*. 2022;25:297-309. (IHC-PS)
19. Kalimuddin S, Tham CY, Qui M, de Alwis R, Sim JX, Lim JM, et al. Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. *Med*. 2021;2:682-88. (Multiplex)
20. Aitken EH, Damelang T, Ortega-Pajares A, Alemu A, Hasang W, Dini S, et al. Developing a multivariate prediction model of antibody features associated with protection of malaria-infected pregnant women from placental malaria. *Elife*. 2021;10:e65776. (Multiplex)
21. SouthernBiotech unpublished data (IHC-FS, ICC)

Spectral Red® is a registered trademark of Southern Biotechnology Associates, Inc.

Spectral Red® is a PE/CY5 tandem conjugate.

Texas Red® is a registered trademark of Molecular Probes, Inc.

Cy™ is a trademark of Cytiva or one of its subsidiaries.

TB7105

01-May-24

Corporate Offices: 160 Oxmoor Blvd • Birmingham, AL 35209 • USA **Mailing Address:** P.O. Box 26221 • Birmingham, AL 35260 • USA

Tel: 205.945.1774 • U.S. and Canada: 800.722.2255 • **Fax:** 205.945.8768

Email: info@southernbiotech.com • **Website:** www.southernbiotech.com